Recombinant vs Synthetic Peptides: How Production Routes Differ

In plain English

There are two ways to obtain a defined peptide in quantity.

The chemical route is solid-phase peptide synthesis (SPPS). The chain is built on an insoluble resin bead, one amino acid at a time, with every reactive group except the one being joined blocked by a protecting group ^[1]. Nothing living is involved, and the chemist chooses each building block.

The biological route is recombinant expression. The DNA sequence coding for the peptide is placed in a host cell, usually a bacterium, and the cell’s ribosome translates it. The peptide is then separated from everything else the cell contains ^{[4, 6]}.

Each route leaves its own fingerprint. A synthetic peptide carries chemical by-products: chains missing a residue, chains with an extra residue, left-over protecting-group fragments and the acid counter-ion from purification ^[15]. A recombinant peptide carries biological ones: proteins from the host cell, host DNA, and bacterial endotoxin ^{[9, 16]}.

The short version

• Synthesis builds the chain chemically; expression has a cell translate it ^{[1, 6]}.
• Synthesis accepts unnatural residues; translation is mostly limited to the encoded twenty ^{[1, 13]}.
• The two routes leave completely different impurity profiles ^{[9, 15, 16]}.

Key facts

The chemical route, in outline

Merrifield’s 1963 paper introduced the idea that still defines the field: anchor the growing chain to an insoluble support, so that reagents and by-products can be washed away at each step while the product stays behind ^[1]. Each round adds one residue by deprotecting the chain’s free amine, coupling the next activated amino acid, and washing. The chain is cleaved from the resin at the end, and purified, usually by reversed-phase chromatography.

Two consequences follow from the arithmetic. First, yield compounds: a 50-residue chain needs about a hundred near-quantitative reactions in a row, so a small per-step shortfall becomes a large shortfall overall. Second, every imperfect step writes an impurity into the batch. European guidance on synthetic peptides names the families directly: deletion sequences, where a residue is missing after an incomplete coupling or deprotection; truncated sequences, produced when unreacted sites are capped by acetylation; and insertion sequences, where a residue is added twice in one coupling step ^[15].

Chemistry has pushed hard against the length limit. Automated fast-flow instruments have assembled chains up to 164 residues through 327 consecutive reactions, with elongation complete in hours, and nine protein chains made that way folded to give properties comparable to the biologically expressed versions ^[2]. A different approach joins two purified fragments: native chemical ligation reacts two unprotected segments to give a thioester-linked intermediate that rearranges spontaneously into a native peptide bond at the junction ^[3]. Fragment condensation in solution, after making the fragments by SPPS, is a recognised hybrid manufacturing approach, and European guidance expects comparability data when more than one process is run in parallel ^[15].

The chemical route also carries an environmental cost that the literature frames as a design problem rather than a footnote. A cross-industry review described current practice as relying on legacy technologies with large amounts of hazardous reagents and solvents, and identified greener processes for peptide active ingredients as an unmet need ^[14]. The mechanics of the chemical route are set out in How Research Peptides Are Made.

The biological route, in outline

Escherichia coli is the most widely used expression host, with a large catalogue of plasmids, engineered strains and cultivation strategies behind it ^[6]. The gene for the target is cloned into an expression plasmid, the host is grown, expression is induced, and the cells are harvested and broken open.

Short peptides are rarely expressed on their own. A review of recombinant antimicrobial peptide production in E. coli explains why: these peptides are usually expressed as fusion proteins, because fusing them to a carrier masks their effect on the host and protects them from the host’s own proteases ^[4]. The carrier then has to be removed, chemically or enzymatically, and the free peptide repurified.

Fusion partners are chosen for what they add. A widely cited overview catalogues the common affinity tags, among them His-tag, glutathione S-transferase, maltose-binding protein, thioredoxin, NusA and Strep-tag, and notes how hard it is to pick the right system for a given target in advance ^[5]. Some tags mainly aid purification; others improve solubility or discourage aggregation.

When expression outruns folding, the product accumulates as inclusion bodies: dense particles of densely packed, largely denatured chains. Getting active material back out of them is described as cumbersome and low-yielding, and it accounts for a major share of the cost of recombinant production in E. coli ^[7]. Mild solubilisation, which preserves the native-like secondary structure that inclusion-body aggregates retain, returned more than 40% of the inclusion-body protein in one worked case ^[7].

Where the routes genuinely diverge

Chemical space

Translation reads the genetic code, so it builds chains from the canonical amino acids. Synthesis has no such constraint: D-residues, N-methylated residues, non-natural side chains and backbone modifications are ordinary building blocks on a resin ^[1]. Biology can be extended to some of this, but it takes work. Genetic code expansion commonly allows one type of non-canonical amino acid to be encoded, and recent strategies, including quadruplet codon reading, non-natural DNA base pairs and recoded genomes, aim at several distinct ones ^[13].

C-terminal amidation

Many natural peptides end in an amide rather than a free acid. On resin, this is a choice of linker. In a cell, it requires an enzyme. A 1993 process illustrates the gap: a glycine-extended 32-residue precursor was expressed in E. coli as a glutathione S-transferase fusion, cleaved from the carrier with cyanogen bromide, and only then converted enzymatically to the amidated form by a recombinant amidating enzyme secreted from Chinese hamster ovary cells, with the disulfide bond re-formed afterwards ^[10]. Four operations in the biological route replace one decision in the chemical one. Modifications of this kind are covered in Peptide Modifications Explained.

Fidelity, and how it fails

Both routes make mistakes, but different ones.

Chemical errors are positional and chemical: a coupling that did not finish, a residue added twice, a protecting group that left a reactive fragment behind that then attacked a sensitive side chain such as tryptophan, tyrosine or methionine ^[15]. Stereochemistry can also slip; that failure mode is covered in Chirality in Peptides.

Biological errors come from metabolism. E. coli synthesises the non-canonical amino acids norleucine and norvaline as by-products of branched-chain amino acid metabolism, and these can be misincorporated in place of methionine or other residues. A high level of norleucine misincorporation was found in one methionine-rich recombinant product expressed in E. coli K12; adding methionine to the medium helped but did not solve it, while changing the fed-batch control strategy, medium and feed minimised it, and expressing the same product in E. coli BL21(DE3) showed the problem was largely strain-specific ^[11]. A separate fermentation study found that norleucine and norvaline accumulated only when molybdenum, nickel and selenium were absent; adding those trace elements cut them to detection-limit levels under deliberately oxygen-limited, glucose-excess conditions ^[12]. Both are process-control findings: the same gene in the same organism can give a different impurity profile depending on how the fermenter was run.

Two different impurity problems

Host cell proteins deserve a note of their own, because they are the clearest example of an impurity class with no chemical analogue. A multi-company review of industry experience records cases where residual host cell protein reached levels of concern, and observes that regulatory guidance asks for products to be as pure as practical without a single numerical limit, because the risk depends on the product and the particular impurity ^[9]. ICH Q6B describes the assay expectation: a sensitive method, typically an immunoassay raised against a preparation of the production cell minus the product-coding gene ^[16]. Endotoxin is likewise a recombinant-specific concern, and its removal from biological preparations has its own literature of adsorption, partitioning, ultrafiltration and chromatographic methods ^[8]. Endotoxin measurement is covered in Endotoxin (LAL) Testing Explained, and batch-level impurity reporting in Common Impurities in Synthetic Peptides.

How the guidance splits the two

The regulatory frameworks are deliberately separate, which is a useful way to see how different the two routes are considered to be.

• European guidance on the development and manufacture of synthetic peptides addresses solid-phase synthesis and fragment condensation, and states that it does not apply to biological and biotechnological products manufactured by recombinant technologies ^[15].
• ICH Q6B, which sets specifications for biotechnological and biological products, applies to proteins and polypeptides produced from recombinant or non-recombinant cell-culture expression systems, and explicitly does not cover synthetic peptides and polypeptides ^[16].
• Where the same molecule exists both ways, the comparison is analytical rather than assumed. European guidance notes that the biosimilar pathway is not available for a chemically synthesised peptide, because it falls outside the definition of a biological substance, and that a broad panel of methods is needed to demonstrate comparability between a recombinant reference product and a synthetic version, with all differences quantified ^[15].

That last point is worth restating plainly: two preparations of the same sequence, one grown and one built, are not assumed to be interchangeable without data.

Which route suits which molecule

No rule decides this, but the published practice points in consistent directions.

What this means in Australia

• The route is part of the specification. Because the two routes leave different impurities, a batch report is only interpretable if the route is known. European guidance expects the control strategy for a synthetic peptide to address related substances arising from the process and the starting materials ^[15]; ICH Q6B expects process-related impurity testing tied to the cell substrate and cell culture ^[16].
• Accredited testing. The National Association of Testing Authorities (NATA) accredits Australian laboratories to ISO/IEC 17025, the international standard for the competence of testing and calibration laboratories ^[17]. Accreditation speaks to method control, not to which production route was used.
• Production route does not change legal status. Status under the current Poisons Standard (October 2026) attaches to the substance named there; several peptides are listed in Schedule 4 (prescription only) and Appendix D, clause 5 (possession without authority is illegal) ^[18]. Whether material was grown or built does not alter that.
• Labels do not change status. The TGA has stated that a “research use only” disclaimer does not make supply lawful, and does not change a product’s regulatory status, permit importation, or remove advertising or supply obligations ^[19].

This is general information, not legal advice. Laws change; check the current Poisons Standard and TGA guidance.

Frequently asked questions

What is the difference between a recombinant and a synthetic peptide?

A synthetic peptide is assembled chemically, usually by solid-phase synthesis on a resin ^[1]. A recombinant peptide is translated by a living host cell carrying the gene for it, then purified away from the cell’s contents ^{[4, 6]}.

Can both routes make the same molecule?

For a sequence of standard L-amino acids, yes. The two preparations are not assumed to be equivalent, though: European guidance expects a broad analytical panel to demonstrate comparability between a recombinant product and a synthetic version, with any differences quantified ^[15].

Why are short peptides expressed as fusion proteins?

Because a free short peptide can harm the host and is rapidly degraded inside it. Fusing it to a carrier protein masks that effect and shields it from host proteases; the carrier is then cleaved off ^[4].

What impurities are specific to recombinant production?

Host cell proteins, host DNA and endotoxin, none of which can arise from a purely chemical process ^{[8, 9, 16]}. Misincorporation of metabolic by-products such as norleucine is also specific to the biological route ^{[11, 12]}.

How long a chain can chemical synthesis reach?

Classical stepwise synthesis is routine up to roughly fifty residues. Automated fast-flow chemistry has produced chains of up to 164 residues over 327 consecutive reactions, and native chemical ligation joins purified fragments into longer chains ^{[2, 3]}.

Does the production route affect how material should be stored?

Not directly; storage follows the molecule’s own stability. General laboratory practice is covered in Peptide Storage and Stability.

References

1. Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963;85(14):2149–2154. doi:10.1021/ja00897a025
2. Hartrampf N, Saebi A, Poskus M, et al. Synthesis of proteins by automated flow chemistry. Science. 2020;368(6494):980–987. doi:10.1126/science.abb2491. PMID: 32467387
3. Dawson PE, Muir TW, Clark-Lewis I, Kent SB. Synthesis of proteins by native chemical ligation. Science. 1994;266(5186):776–779. doi:10.1126/science.7973629. PMID: 7973629
4. Li Y. Recombinant production of antimicrobial peptides in Escherichia coli: a review. Protein Expr Purif. 2011;80(2):260–267. doi:10.1016/j.pep.2011.08.001. PMID: 21843642
5. Terpe K. Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems. Appl Microbiol Biotechnol. 2003;60(5):523–533. doi:10.1007/s00253-002-1158-6. PMID: 12536251
6. Rosano GL, Ceccarelli EA. Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol. 2014;5:172. doi:10.3389/fmicb.2014.00172. PMID: 24860555
7. Singh SM, Panda AK. Solubilization and refolding of bacterial inclusion body proteins. J Biosci Bioeng. 2005;99(4):303–310. doi:10.1263/jbb.99.303. PMID: 16233795
8. Magalhães PO, Lopes AM, Mazzola PG, Rangel-Yagui C, Penna TC, Pessoa A Jr. Methods of endotoxin removal from biological preparations: a review. J Pharm Pharm Sci. 2007;10(3):388–404. PMID: 17727802
9. Vanderlaan M, Zhu-Shimoni J, Lin S, Gunawan F, Waerner T, Van Cott KE. Experience with host cell protein impurities in biopharmaceuticals. Biotechnol Prog. 2018;34(4):828–837. doi:10.1002/btpr.2640. PMID: 29693803
10. Ray MV, Van Duyne P, Bertelsen AH, et al. Production of recombinant salmon calcitonin by in vitro amidation of an Escherichia coli produced precursor peptide. Biotechnology (N Y). 1993;11(1):64–70. doi:10.1038/nbt0193-64. PMID: 7763486
11. Ni J, Gao M, James A, et al. Investigation into the misincorporation of norleucine into a recombinant protein vaccine candidate. J Ind Microbiol Biotechnol. 2015;42(6):971–975. doi:10.1007/s10295-015-1613-x. PMID: 25841644
12. Biermann M, Linnemann J, Knüpfer U, et al. Trace element associated reduction of norleucine and norvaline accumulation during oxygen limitation in a recombinant Escherichia coli fermentation. Microb Cell Fact. 2013;12:116. doi:10.1186/1475-2859-12-116. PMID: 24261588
13. de la Torre D, Chin JW. Reprogramming the genetic code. Nat Rev Genet. 2021;22(3):169–184. doi:10.1038/s41576-020-00307-7. PMID: 33318706
14. Isidro-Llobet A, Kenworthy MN, Mukherjee S, et al. Sustainability challenges in peptide synthesis and purification: from R&D to production. J Org Chem. 2019;84(8):4615–4628. doi:10.1021/acs.joc.8b03001. PMID: 30900880
15. European Medicines Agency. Guideline on the development and manufacture of synthetic peptides. EMA/CHMP/CVMP/QWP/367182/2025. Adopted 4 December 2025; effective 1 June 2026. ema.europa.eu. Accessed 25 October 2026.
16. International Council for Harmonisation. ICH Q6B: Specifications: test procedures and acceptance criteria for biotechnological/biological products. database.ich.org. Accessed 25 October 2026.
17. National Association of Testing Authorities, Australia (NATA). Accreditation programs, including ISO/IEC 17025 testing and calibration. nata.com.au. Accessed 25 October 2026.
18. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327). Federal Register of Legislation. legislation.gov.au/F2026L01327/latest/text. Accessed 25 October 2026.
19. Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety advisory, 13 April 2026. tga.gov.au. Accessed 25 October 2026.